https://doi.org/10.4081/aiua.2021.1.84
Clinical impact of combined PTEN and ERG rearrangements in localized prostate cancer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
To the Editor,
Prostate cancer (PCa) is nowadays the second most common malignancy diagnosed among men and is responsible for one of the leading causes of cancer mortality. Clinically localized disease may present with a wide variety of clinical behavior including tumors of low clinical significance as well as highly aggressive ones. Among patients treated with either radical prostatectomy or radiotherapy there is a risk of biochemical failure (BF). As a result, it is of outmost interest to develop new markers predicting the risk of BF development.
How to Cite
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Charalampos Fragkoulis, Ioannis Glykas, Lazaros Tzelves, Panagiotis Velissarios Stamatakos, Georgios Papadopoulos, Georgios Stathouros, Athanasios Dellis, Konstantinos Ntoumas, Akrivi Kostopoulou, Charalampos Deliveliotis, Athanasios Papatsoris, Clinical impact of ERG and PTEN status in prostate cancer patients underwent radical prostatectomy , Archivio Italiano di Urologia e Andrologia: Vol. 94 No. 4 (2022)
You may also start an advanced similarity search for this article.